Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Base de datos
Asunto principal
Tipo del documento
Intervalo de año
1.
J Community Hosp Intern Med Perspect ; 13(1): 6-10, 2023.
Artículo en Inglés | MEDLINE | ID: covidwho-2284029

RESUMEN

As the novel COVID-19 pandemic was on the rise, its impact on the healthcare system was devastating. Patients became more reluctant to present to the hospital and elective procedures were being postponed for patient safety. We wanted to assess the effects of the COVID-19 pandemic on the door-to-device time in our small community hospital in the heart of Trenton, New Jersey. We created a retrospective study that evaluated all STEMI cases that presented to our institute from January 2018 until the end of May, 2021. Our primary outcome was the door-to-device time. Secondary outcomes were the length of hospital stay, ICU admission, length of ICU stay, cardiac arrest, and death during the hospitalization. We studied 114 patients that presented with STEMI to our emergency department, 77 of these patients presented pre-COVID-19, and 37 presented during the pandemic. Our median door-to-device for STEMI cases pre-COVID-19, and during the pandemic were 70 min (IQR 84-57) and 70 min (IQR 88-59) respectively with no significant difference found (P-value 0.55, Mann Whitney Test). It is, however, interesting to note that the number of STEMI admissions significantly decreased during the pandemic era. There are limitations to our study, most noticeably the number of STEMI cases at our small community hospital which limits its generalizability. Moreover, we did not assess other comorbidities which might have confounded our outcomes and we were also unable to follow patients post-discharge to assess the long-term sequela of their STEMI admission. Therefore, more dedicated studies of this clinical conundrum are required to further assess and implement guidelines for the future.

2.
Ann Clin Lab Sci ; 52(6): 863-870, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: covidwho-2169182

RESUMEN

OBJECTIVE: The true case fatality rate (CFR) of a disease outbreak can only be ascertained after all cases and deaths have been tabulated at the end of the epidemic. We define a metric, the interim case fatality rate (ICFR) which is the incremental change in the ratio of cases to deaths. To examine longitudinal changes in the ICFR of the COVID-19 pandemic and to evaluate the likelihood that the ICFR can predict the final CFR. METHODS: Publicly available databases were used to gather data on the number of cases and deaths in Europe and the United States (USA). These data were gathered over the period from Mar.1, 2020 to Aug. 15, 2021, on four regions of the USA and four regions of Europe on a bi-weekly basis. Statistical methods were utilized to evaluate changes over the final month of the study (July 15, 2021 to August 15, 2021). Stability of the ICFR was based on acceptance of the null hypothesis that no significant difference (p>0.05) was observed over that period. RESULTS: In all regions studied, the early months of the pandemic were marked by very high ICFRs. By late 2020, these began to stabilize at levels well below 5%. During the final month of the study, only one (Northeast USA) of the eight regions evaluated showed a statistically significant difference in ICFR. Mean ICFR projections, based on weighted values of cases are 1.8% (95% CI: 1.2% to 2.3%) for the USA and 2.1% (95% CI: 1.5% 2.7% for Europe. CONCLUSION: After an early peak, very little change was observed in the ICFR, and by summer 2021, the rates had stabilized. Weighted ICFR for all regions may well reflect the final ICFR.


Asunto(s)
COVID-19 , Estados Unidos/epidemiología , Humanos , COVID-19/epidemiología , Pandemias , SARS-CoV-2 , Europa (Continente)/epidemiología , Brotes de Enfermedades
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA